Catalys Pacific

Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences, particularly biotherapeutics, MedTech, diagnostics, and biotechnology. Founded in 2019, the firm operates with offices in Tokyo, Japan, and San Francisco, California, aiming to bridge innovation ecosystems between Japan and the United States. Catalys Pacific's mission is to provide healthcare solutions for patients worldwide by creating and investing in bioventure companies that drive innovation in life sciences. The firm leverages its extensive global network and local presence in both Japan and the United States to access differentiated sourcing and early-stage investment opportunities. This transpacific partnership approach enables Catalys Pacific to create and develop bespoke biotech companies on both sides of the Pacific, maximizing therapeutic impact for patients globally while generating attractive risk-adjusted returns for investors. The firm's portfolio includes companies such as Mineralys Therapeutics, focused on developing novel therapies for hypertension, and Renalys Pharma, committed to innovative therapeutics for renal disease. Catalys Pacific's investment strategy emphasizes hands-on management, deep due diligence, and a network-driven approach to foster transformative life science solutions and facilitate global market entry, particularly between the U.S. and Japan. The firm maintains a strictly independent governance structure that ensures autonomous assessment and decision-making of its investments. Catalys Pacific's team consists of professionals with broad experience in academia, biotechnology, venture capital, and the pharmaceutical industry, dedicated to improving patient lives worldwide through impactful healthcare innovations.